Access the latest updates including news, publications, activities from FIP and its constituencies, on this page. Discover what happened at FIP this month, explore recent announcements and campaigns, and browse the archived news in case you missed any.
Stay up to date by following us on social media (Facebook, Instagram, LinkedIn, X) and subscribing to our newsletters. Share the news with your networks and help amplify the work of FIP globally.
Pharmacists should be empowered to lead evidence-based pharmaceutical product selection, including generic substitution and therapeutic interchange, to improve access to medicines, strengthen health system resilience and optimise patient outcomes, according to a new FIP Statement of Policy released today.
Replacing FIP’s 2018 policy on pharmacists’ authority in pharmaceutical product selection, the statement reflects developments in regulatory science, the growing use of generic and biosimilar medicines, digital health technologies, medicine shortages and the need for sustainable, people-centred health care.
The policy recognises pharmaceutical product selection as a key clinical responsibility of pharmacists. Where permitted by national legislation, pharmacists should be able to apply evidence-based clinical judgement to optimise medicine use, maintain continuity of care and support equitable access to treatment.
FIP calls for clear legal frameworks, aligned regulatory and reimbursement policies, and investment in pharmacist education, digital infrastructure and collaborative models of care to support medicines optimisation.